Comparative Pharmacology
Head-to-head clinical analysis: METAGLIP versus PRANDIMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAGLIP versus PRANDIMET.
METAGLIP vs PRANDIMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin decreases hepatic glucose production and intestinal absorption, and improves insulin sensitivity; glipizide stimulates insulin secretion from pancreatic beta cells by inhibiting ATP-sensitive potassium channels.
PRANDIMET combines repaglinide (a meglitinide analog) and metformin (a biguanide). Repaglinide lowers blood glucose by stimulating insulin release from pancreatic beta cells via closure of ATP-sensitive potassium channels, leading to calcium influx and exocytosis of insulin. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Oral: Initial 2.5 mg/250 mg once daily with breakfast, titrate gradually to maximum 20 mg/2000 mg per day in divided doses twice daily.
Initial dose: 1.25 mg repaglinide/250 mg metformin orally twice daily with meals. Maximum dose: 10 mg repaglinide/2500 mg metformin per day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically, dosing adjustments required in renal impairment with CrCl <60 mL/min
Terminal elimination half-life: 1-1.5 hours. Clinically, repaglinide has a short half-life, allowing for flexible dosing immediately before meals.
Renal: 90-95% unchanged; biliary/fecal: <5% as metabolites
Renal: ~90% (60% as repaglinide metabolites, 30% as unchanged repaglinide); Biliary/fecal: ~8%
Category C
Category C
Antidiabetic Combination
Antidiabetic Combination